Analyst Price Target is $2.75
▲ +266.28% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Lucid Diagnostics in the last 3 months. The average price target is $2.75, with a high forecast of $3.00 and a low forecast of $2.50. The average price target represents a 266.28% upside from the last price of $0.75.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Lucid Diagnostics. This Buy consensus rating has held steady for over two years.
Lucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Read More